Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Boudewijn L. M. de Jonge"'
Publikováno v:
Journal of Antimicrobial Chemotherapy. 75:1165-1173
Objectives To determine the spread of ESBLs and carbapenemases in Enterobacterales and Pseudomonas aeruginosa in Europe. Methods 45 335 Gram-negative bacilli were collected in 18 European countries as part of the International Network for Optimal Res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d171c3b2194eff9d27b90f7e7a9a40c
https://doi.org/10.1093/jac/dkz571
https://doi.org/10.1093/jac/dkz571
Autor:
Daniel F. Sahm, Boudewijn L M de Jonge, James A. Karlowsky, Krystyna M. Kazmierczak, Gregory G. Stone
Publikováno v:
Antimicrob Agents Chemother
To estimate the incidence of carbapenem-resistant Enterobacterales (CRE), a global collection of 81,781 surveillance isolates of Enterobacterales collected from patients in 39 countries in five geographic regions from 2012 to 2017 was studied. Overal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb8149799dafe2221107b7d56fa84b90
https://doi.org/10.1128/aac.02000-20
https://doi.org/10.1128/aac.02000-20
Publikováno v:
Journal of Antimicrobial Chemotherapy. 73:2777-2781
Objectives The activity of ceftazidime/avibactam was assessed against 5716 Pseudomonas aeruginosa isolates collected from 96 medical centres in 18 European countries as part of the International Network for Optimal Resistance Monitoring (INFORM) glob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6396396e6b7c89ee046e29b4af8b13fa
https://doi.org/10.1093/jac/dky267
https://doi.org/10.1093/jac/dky267
Publikováno v:
Journal of Antimicrobial Chemotherapy. 73:2782-2788
Objectives The activity of ceftazidime/avibactam was assessed against 24 750 isolates of Enterobacteriaceae collected from 96 medical centres in 18 European countries as part of the International Network for Optimal Resistance Monitoring (INFORM) glo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::586140a3bd55d073709488cfe01633e9
https://doi.org/10.1093/jac/dky266
https://doi.org/10.1093/jac/dky266
Autor:
Gregory G. Stone, Krystyna M. Kazmierczak, Samuel K. Bouchillon, James A. Karlowsky, Boudewijn L. M. de Jonge, Daniel F. Sahm
The in vitro activities of ceftazidime-avibactam and comparators against 9,149 isolates of Enterobacteriaceae and 2,038 isolates of Pseudomonas aeruginosa collected by 42 medical centers in nine countries in the Asia-Pacific region from 2012 to 2015
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de94cb92dd8e69055d08b2f8decfe036
https://europepmc.org/articles/PMC6437529/
https://europepmc.org/articles/PMC6437529/
Autor:
Patricia A. Bradford, Daniel F. Sahm, Gregory G. Stone, Krystyna M. Kazmierczak, Boudewijn L. M. de Jonge
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
Enterobacteriaceae producing the Ambler class D OXA-48 carbapenemase, combined with additional resistance mechanisms, such as permeability defects or cocarriage of class A, B, or C β-lactamases, can become highly resistant to most β-lactams current
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47129ea4cc061c5cee282755d8a84392
https://doi.org/10.1128/aac.00592-18
https://doi.org/10.1128/aac.00592-18
Autor:
Sharon Rabine, Meredith Hackel, Douglas J. Biedenbach, Daniel F. Sahm, Samuel K. Bouchillon, Krystyna M. Kazmierczak, Patricia A. Bradford, Boudewijn L. M. de Jonge
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:4490-4500
The Klebsiella pneumoniae carbapenemase (KPC), first described in the United States in 1996, is now a widespread global problem in several Gram-negative species. A worldwide surveillance study collected Gram-negative pathogens from 202 global sites i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffa583ad544cdd820531f93271acfa05
https://doi.org/10.1128/aac.00107-16
https://doi.org/10.1128/aac.00107-16
Autor:
Gregory G. Stone, Douglas J. Biedenbach, Samuel K. Bouchillon, Krystyna M. Kazmierczak, Boudewijn L. M. de Jonge, Meredith Hackel, Daryl J. Hoban
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:4677-4683
Increasing resistance in Gram-negative bacilli, including Klebsiella spp., has reduced the utility of broad-spectrum cephalosporins. Avibactam, a novel non-β-lactam β-lactamase inhibitor, protects β-lactams from hydrolysis by Gram-negative bacteri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4daa5591c87fea89693da3b5f630197a
https://doi.org/10.1128/aac.02841-15
https://doi.org/10.1128/aac.02841-15
Autor:
Krystyna M. Kazmierczak, Wright W. Nichols, Boudewijn L. M. de Jonge, Daniel F. Sahm, James A. Karlowsky
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:4743-4749
Broth microdilution antimicrobial susceptibility testing was performed for ceftazidime-avibactam and comparator agents against 7,062 clinical isolates of Pseudomonas aeruginosa collected from 2012 to 2014 in four geographic regions (Europe, Asia/Sout
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c108979722d4bfbc028106db09fcf4bf
https://doi.org/10.1128/aac.00220-16
https://doi.org/10.1128/aac.00220-16
Autor:
Wright W. Nichols, Boudewijn L. M. de Jonge, Krystyna M. Kazmierczak, Douglas J. Biedenbach, James A. Karlowsky, Daniel F. Sahm
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:3163-3169
The activity of ceftazidime-avibactam was assessed against 961 isolates of meropenem-nonsusceptible Enterobacteriaceae . Most meropenem-nonsusceptible metallo-β-lactamase (MBL)-negative isolates (97.7%) were susceptible to ceftazidime-avibactam. Iso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1556ed95ea02df838e6e7d603eb9b3b8
https://doi.org/10.1128/aac.03042-15
https://doi.org/10.1128/aac.03042-15